However, novel compounds targeting tumor‐specific molecular changes, such as EGFR and BRAF mutations, and ALK fusions, or immunomodulatory agents activating anti‐tumor immune responses, are challenging this paradigm, and some of these drugs show intracerebral efficacy.3, 4, 5, 8, 11. The gene discussed is BRAF; the disease is neoplasm.